Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Breast Neoplasms 3Hereditary Sensory and Autonomic Neuropathies 2Endometrial Neoplasms 2Advanced Nonhematologic Malignancies 2Waldenstrom Macroglobulinemia 1Recurrence 1Non-hematologic Malignancy 1Multiple Myeloma 1Lung Neoplasms 1Hematologic Neoplasms 1Genital Diseases 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Endometrioid 1Advanced Solid Tumors 1Advanced Solid Malignancies 1Advanced Nonhematological Neoplasms 1

Interventions

zanubrutinib 9ibrutinib 9Rituximab 5idelalisib 4venetoclax 3pirtobrutinib 3ublituximab 2bazlitoran 2acalabrutinib 2Dexamethasone 2ARQ531 2umbralisib 1selinexor 1sapanisertib 1pomalidomide 1perifosine 1pembrolizumab 1ontuxizumab 1ofatumumab 1obinutuzumab 1mavorixafor 1loncastuximab tesirine 1fludarabine 1epratuzumab 1enzastaurin 1carfilzomib 1brexucabtagene autoleucel 1WW Domain-Containing Oxidoreductase 1Voriconazole 1Vitamin B 12 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Waldenstrom Macroglobulinemia × sapanisertib × Clear all
NCT01118689 2013-08-02

Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia

Millennium Pharmaceuticals, Inc.

Phase 1 Completed
39 enrolled
LymphoidPlasma cell

Waldenstrom Macroglobulinemia, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡